The companion app for women on Mounjaro
Features
One app.
Built for Mounjaro.
Lina brings together shot tracking, side-effect logs, weight progress, and nutrition reminders - so you can focus on feeling good, not managing notes or spreadsheets.


The stuff nobody else does
✅ Medication reminders for pills and injections
✅ Injection site rotation (optional)
✅ Weight smoothing (hides noise, shows real trend)
✅ Non-scale victory logging
✅ Daily check-ins for mood, energy, side effects
✅ 900+ Wegovy-specific insights (science, mindset)
✅ Progress photos with side-by-side comparison
✅ Hydration tracking in cups, ml and oz
✅ Food tracking focused on protein + meal quality
✅ Streak system with freeze days
✅ Calculations and goals backed by research
✅ Community voting (choose the next feature)
✅ Doctor-ready PDF summaries
Questions about Lina? We’re happy to answer anything for you.
Find answers to the most common questions about
using your companion.
Why Mounjaro
Mounjaro isn't just another GLP-1. It's the first dual-action medication — targeting both GLP-1 and GIP receptors. In plain terms: it works on two pathways instead of one.
The results speak for themselves. In the SURMOUNT-1 trial, participants taking the highest dose lost an average of 20.9% of their body weight over 72 weeks.¹ For a 200lb woman, that's over 40 pounds. More than one in three participants lost 25% or more.
Head-to-head, tirzepatide outperformed semaglutide. The SURPASS-2 trial showed Mounjaro delivered greater blood sugar reduction and more weight loss than Ozempic at comparable doses.²
What makes Mounjaro different isn't just the numbers — it's how women describe feeling on it. In clinical trials, participants reported less hunger and more satisfaction after meals compared to other GLP-1s. The dual mechanism seems to hit appetite from multiple angles.³
Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216.
Frías JP, et al. N Engl J Med. 2021;385(6):503-515.
Rosenstock J, et al. Lancet. 2021;398(10295):143-155.
Shi Q, et al. Obesity Reviews. 2024;25(2):e13652.





















